Cardiotoxicity evaluation using human embryonic stem cells and induced pluripotent stem cell-derived cardiomyocytes by Qi Zhao et al.
RESEARCH Open Access
Cardiotoxicity evaluation using human
embryonic stem cells and induced
pluripotent stem cell-derived
cardiomyocytes
Qi Zhao1†, Xijie Wang1†, Shuyan Wang1, Zheng Song1, Jiaxian Wang2 and Jing Ma1*
Abstract
Background: Cardiotoxicity remains an important concern in drug discovery. Human pluripotent stem cell-derived
cardiomyocytes (hPSC-CMs) have become an attractive platform to evaluate cardiotoxicity. However, the consistency
between human embryonic stem cell-derived cardiomyocytes (hESC-CMs) and human induced pluripotent stem
cell-derived cardiomyocytes (hiPSC-CMs) in prediction of cardiotoxicity has yet to be elucidated.
Methods: Here we screened the toxicities of four representative drugs (E-4031, isoprenaline, quinidine, and
haloperidol) using both hESC-CMs and hiPSC-CMs, combined with an impedance-based bioanalytical method.
Results: It showed that both hESC-CMs and hiPSC-CMs can recapitulate cardiotoxicity and identify the effects of well-
characterized compounds.
Conclusions: The combined platform of hPSC-CMs and an impedance-based bioanalytical method could improve
preclinical cardiotoxicity screening, holding great potential for increasing drug development accuracy.
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Background
Cardiac toxicity remains a major cause of restriction or
withdrawal of drugs from the market [1]. Between 1990
and 2001, eight non-cardiovascular drugs were with-
drawn at an estimated cost of $12 billion due to drug-
induced arrhythmias [2]. Indeed, it is estimated that up
to 90% of compounds that pass pre-clinical screening fail
at clinical trial level, with cardiotoxicity accounting for
45% alone [3]. Current in vitro cardiotoxicity screenings
rely on the artificial expression of a single hERG channel
in Chinese hamster ovary or human embryonic kidney
cells, based on the two guidelines ICH S7B and ICH E14
[4, 5]. Yet, the sole reliance on simplified model cell
lines, possessing interspecies differences in ion channels,
biological pathways, and pharmacokinetic properties, is
putting human lives at risk. The human embryonic stem
cell/human induced pluripotent stem cell (hESC/hiPSC)-
derived cardiomyocytes, expressing cardiac-specific factors
and structural proteins, provide an alternative model for
drug screening in vitro.
In combination with state-of-the-art bioanalytical
methods, hESC-CMs have been reported as an alterna-
tive model for in vitro cardiotoxicity [6, 7]. Navarrete
and colleagues [8] reported that hiPSC-CMs can recap-
itulate drug-induced arrhythmias. Although hESC-CMs
and hiPSC-CMs have been reported possessing compar-
able ultrastructural features [9], their responses to
identical compounds have not been systemically com-
pared. The xCELLigence Real-Time Cell Analysis
(RTCA) Cardio system, which utilizes impedance tech-
nology to quantify CM-beating properties, has been
previously reported as an emerging method to quantify
cardiac contractility [10]. In this study, we compared the
capacity of hESC- and hiPSC-CMs for prediction of
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cardiotoxicity on four documented compounds, by
examination with the RTCA Cardio System.
Methods
Human ESC- and iPSC-derived cardiomyocytes
Human ESC-CMs were kindly provided by the Institute
of Biophysics of the Chinese Academy of Sciences,
Beijing, China. Human iPSC-CMs, provided by a domes-
tic manufacturer (Cellapy: CA2001106, Beijing, China),
were also examined. Cells were incubated in maintaining
medium at 37 °C, 5% CO2, with culture medium
refreshed every 2 days. Cells were dissociated and
replated into 96-well E-plates (ACEA Biosciences,
Hangzhou, China), which was pre-coated with 0.1%
gelatin. Cells were plated at a density of 50,000 cells
per well.
Real-time impedance-based bioanalyses of hPSC-derived
cardiomyocytes
Spontaneous cardiomyocytes contraction and cell health
were monitored in real-time by impedance using xCEL-
Ligence real-time cellular analyzer (RTCA) Cardio sys-
tem (ACEA Biosciences, Hangzhou, China). Impedance
signals were monitored and recorded with 20 s record-
ing per sweep.
Chemicals
Four compounds were investigated: quinidine (Sigma-
Aldrich, St. Louis, MO, USA BCBB6721V1; 100 mmol/L
stock solution in DMSO); isoproterenol (Sigma-Aldrich
BCBFF4079V; 10 mmol/L stock solution in DMSO);
haloperidol (Sigma-Aldrich SLBD0516; 10 mmol/L stock so-
lution in DMSO), and E-4031 (Sigma-Aldrich 086K4616V;
0.03 mmol/L stock solution in DMSO). Drug dilu-
tions were equilibrated in a 37 °C, 5% CO2 incubator
for 30 min before being applied to E-plates.
Data analysis and statistics
For data analysis, cellular impedance index, beat rate,
and amplitude were measured off-line using RTCA
Cardio software 1.0 and normalized for each well to the
baseline (pre-dose) values measured prior to the
compounds treatment. Statistics were performed using
SPSS 21.0 (IBM Corp., Armonk, NY, USA). Data were
presented as mean ± SEM. Statistical significance of
differences was estimated by one-way ANOVA or Student’s
t test. p < 0.05 was considered significant.
Results
HPSC-CMs exhibit a functional cardiomyocytes phenotype
in culture
Spontaneous contracting cardiomyocytes were observed
using light microscopy of both hESC- and hiPSC-CMs.
The cell index (CI) value, which represents the viability
of hPSC-CMs, was greatly affected by medium change
(Fig. 1a–d).The spontaneous beating rate of hiPSC-CMs
was stable at around 100 bpm, with rhythmic irregularity
less than 10%. On the other hand, hESC-CMs possessed
a beating rate around 30 bpm, with rhythmic irregularity
less than 30%.
The effects of E-4031 on hESC- and hiPSC-CMs
E-4031 investigation was performed using various
concentrations (10, 30, 100, and 300 nmol/L), among
which 100 and 300 nmol/L E-4031 substantially re-
duced the CI of hiPSC-CMs (Fig. 2a) and gradually
Fig. 1 The growth curve and transient pulse patterns of hiPSC-CMs and hESC-CMs. a The growth curve of hiPSC-CMs; b The transient pulse
patterns of the hiPSC-CMs; c The growth curve of hESC-CMs; d The transient pulse patterns of hESC-CMs. Data are shown as mean ± SEM, n = 4.
hESC-CMs human embryonic stem cells-derived cardiomyocytes, hiPSC-CMs human induced pluripotent stem cells-derived cardiomyocytes
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weakened the pulse signals (Fig. 2b). Spontaneous
beating rates of hiPSC-CMs were markedly reduced
by 100 nmol/L 6 h after administration and ceased at
12 h. On the other hand, 300 nmol/L significantly re-
duced the spontaneous beating rate 1 h after adminis-
tration and abolished spontaneous activity 2 h post
administration. The amplitudes of CI were also re-
duced in parallel with the decrease of spontaneous
rhythms. Reduction of CI amplitude was also observed in
low concentration (30 nmol/L) E-4031 with 18 h culture,
which tended to recover at 24 h post administration.
Calculation of the concentration-dependent effect on
hiPSC-CMs revealed a 0.04 μmol/L IC50 of E-4031
(Table 1). In comparison, E-4031 increased the CI of
hESC-CMs (Fig. 2c). Reduction of spontaneous beating
rate was observed in all concentrations of E-4031 upon
immediate administration. Ten, 30, and 100 nmol/L of E-
4031 ceased spontaneous activity at 6 h post administra-
tion, while 300 nmol/L of E-4031 ceased spontaneous
beating at 0.5 h post administration (Fig. 2d). Cells recov-
ered automaticity 24 h in the 10 nmol/L group. Interest-
ingly, temporary recovery of spontaneous beating activity
was observed at 18 h in the 300 nmol/L group for one
recording. The effects of E-4031 on amplitude were also
investigated. Consistently, the amplitudes also reduced in
parallel with the decrease of cellular automaticity. Calcula-
tion of the concentration-dependent effect on hESC-CMs
demonstrated a 0.02 μmol/L of IC50 of E-4031 (Table 1).
The effects of quinidine on hESC- and hiPSC-CMs
We next assessed a class I antiarrhythmic drug, quinidine,
on hPSC-CMs. Investigations demonstrated that quinidine
reduced the CI of hiPSC-CMs in a concentration-dependent
manner (Fig. 3a), and weakened the amplitudes of pulse sig-
nals at concentrations of 12.5 μmol/L and above (Fig. 3b).
Detailed trace analysis revealed 3.13 μmol/L quinidine mark-
edly reduced the beating rate 0.5 h after administration,
which spontaneously recovered after 1 h. However, high
Fig. 2 The effects of E-4031 on the hiPSC-CMs and hESC-CMs. a The effect of E-4031 on the CI of hiPSC-CMs; b The effect of E-4031 on the transient
pulse patterns of the hiPSC-CMs; c The effect of E-4031 on the CI of hESC-CMs; d The effect of E-4031 on the transient pulse patterns of the hESC-CMs,
x  s, n = 3). Data are shown as mean ± SEM, n = 3. hESC-CMs human embryonic stem cells-derived cardiomyocytes, hiPSC-CMs human induced
pluripotent stem cells-derived cardiomyocytes
Table 1 The comparison of hESC-CMs with hiPSC-CMs
Drug hESC-CMs hiPSC-CMs
CI (μmol•L-1) IC50/EC50 (μmol•L
-1) CI (μmol•L-1) IC50/EC50 (μmol•L
-1)
E-4031 0.01↑ 0.02 0.1↓ 0.04
Isoprenaline 0.1↓ 0.04 1↓ 0.03
Quinidine 100↓ 2.18 100↓ 13.97
Haloperidol NO 0.14 10↓ 5.17
CI cell index, hESC-CMs human embryonic stem cells-derived cardiomyocytes, hiPSC-CMs human induced pluripotent stem cells-derived cardiomyocytes
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concentrations of quinidine (50 and 100 μmol/L) ceased the
cellular automaticity 0.5 h after administration without self-
recovery within the observation period. On the other hand,
intermediate concentration (12.5 μmol/L) substantially re-
duced the amplitude at 0.5 h and 1 h post administration,
which recovered after 2 h. Calculation of the concentration-
dependent effect on hiPSC-CMs revealed a 13.97 μmol/L
IC50 of quinidine (Table 1). On the other hand, despite a sig-
nificant temporary decrease when perfusion of 100 μmol/L
quinidine was initiated, the CI of hESC-CMs was not mark-
edly influenced by various concentrations (Fig. 3c). However,
the pulse signals weakened in a concentration-dependent
manner (≥3.13 μmol/L, Fig. 3d).The spontaneous beating
rates were ceased by 12.5 μmol/L and 50 μmol/L of quini-
dine at 0.5 h post administration, which recovered at 6 h
and 24 h respectively. High concentration (100 μmol/L)
abolished the cellular automaticity without observing self-
recovery. Calculation of the concentration-dependent effect
on hESC-CMs demonstrated a 2.18 μmol/L of IC50 of quini-
dine (Table 1).
The effects of isoprenaline on hESC- and hiPSC-CMs
Investigation of the positive inotropic isoprenaline demon-
strated a decrease of CI of hiPSC-CMs in a concentration-
dependent manner (Fig. 4a). Intermediate and high
concentration of isoprenaline (0.1, 1, and 10 μmol/L) sig-
nificantly increased the beating rate after 0.5 h of adminis-
tration, which recovered at 24 h (Fig. 4b). Consistently,
the amplitude of hPSC-CMs was also increased by 0.1, 1,
and 10 μmol/L of isoprenaline. Calculation of the
concentration-dependent effects on hiPSC-CMs revealed
a 0.03 μmol/L (Table 1) EC50 of isoprenaline.
Similarly, the CI of hESC-CMs was also decreased by
isoprenaline at concentrations ≥0.1 μmol/L (Fig. 4c). Spon-
taneous beating rate was increased 0.5 h post injection of
isoprenaline (0.01 μmol/L) and recovered after 12 h. Cellu-
lar automaticity of hESC-CMs was significantly increased
by intermediate and high concentration of isoprenaline
(0.1, 1, and 10 μmol/L) 0.5 h post injection, and recovered
at 24 h. Calculation of the concentration-dependent effects
on hESC-CMs demonstrated a 0.04 μmol/L EC50 of
isoprenaline (Table 1).
The effects of haloperidol on hESC- and hiPSC-CMs
Haloperidol reduced the CIs and pulse signals of both
hESC- and hiPSC-CMs in a concentration-dependent
manner (Fig. 5a and c). Mild reduction of spontaneous
beating rate was observed upon perfusing hPSC-CMs with
0.1 μmol/L haloperidol, which recovered at 18 h post
administration. Haloperidol at 1 μmol/L significantly re-
duced the beating rate after 0.5 h upon administration,
and haloperidol at 10 μmol/L ceased the cellular automa-
ticity at 0.5 h. Although self-recovery was observed in the
10 μmol/L group at 24 h, the amplitude was significantly
decreased compared with controls. Calculation of the
concentration-dependent effects on hPSC-CMs demon-
strated a 5.17 μmol/L IC50 of haloperidol (Table 1). Con-
sistently, mild reduction of the beating rate was observed
Fig. 3 The effects of quinidine on the hiPSC-CMs and hESC-CMs. a The effect of quinidine on the CI of hiPSC-CMs; b The effect of quinidine on
the transient pulse patterns of the hiPSC-CMs; c The effect of quinidine on the CI of hESC-CMs; d The effect of quinidine on the transient pulse
patterns of the hESC-CMs, x  s, n = 3). Data are shown as mean ± SEM, n = 3. hESC-CMs human embryonic stem cells-derived cardiomyocytes,
hiPSC-CMs human induced pluripotent stem cells-derived cardiomyocytes
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at 6 h in hESC-CMs post administration of low concen-
tration of haloperidol (0.01 μmol/L). Haloperidol at
0.1 μmol/L significantly reduced the spontaneous beating
rate and amplitudes of hESC-CMs. When the concentra-
tion was further increased to 1 μmol/L, cellular automati-
city was ceased at 0.5 h, and partial recovery was observed
at 24 h post administration. On the other hand, high
concentration (10 μmol/L) of haloperidol abolished the
spontaneous beating of hESC-CMs and no self-recovery
was observed during the investigation period. Calculation
of the concentration-dependent effects on hESC-CMs
demonstrated a 0.14 μmol/L IC50 of haloperidol (Table 1).
Fig. 4 The effects of isoprenaline on the hiPSC-CMs and hESC-CMs. a The effect of isoprenaline on the CI of hiPSC-CMs; b The effect of isoprenaline
on the transient pulse patterns of the hiPSC-CMs; c The effect of isoprenaline on the CI of hESC-CMs; d The effect of isoprenaline on the transient pulse
patterns of the hESC-CMs, x  s, n = 3). Data are shown as mean ± SEM, n = 3. hESC-CMs human embryonic stem cells-derived cardiomyocytes, hiPSC-
CMs human induced pluripotent stem cells-derived cardiomyocytes
Fig. 5 The effects of haloperidol on the hiPSC-CMs and hESC-CMs. a The effect of haloperidol on the CI of hiPSC-CMs. b The effect of haloperidol
on the transient pulse patterns of the hiPSC-CMs. c The effect of haloperidol on the CI of hESC-CMs. d The effect of haloperidol on the transient pulse
patterns of the hESC-CMs, x  s, n = 3). Data are shown as mean ± SEM, n = 3. hESC-CMs human embryonic stem cells-derived cardiomyocytes, hiPSC-
CMs human induced pluripotent stem cells-derived cardiomyocytes
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Discussion
The discovery of hPSC-CMs, including hPSC-CMs and
hESC-CMs, has been an attractive in vitro model to
study cardiotoxicity. Many researchers have used hiPSC-
CMs and hESC-CMs as screening models for pro-
arrhythmic compounds during drug development to
circumvent the lack of sufficient and healthy human car-
diac tissue [11–15]. Here we reported the combination
of an RTCA Cardio system and hPSC-CMs as a high-
throughput platform, enabling unbiased real-time kinetic
data acquisition for a more accurate evaluation of the
cardiotoxicity of various compounds. This system can
continuously monitor the contractility of cardiomyocytes
by using noninvasive impedance readout and obtain
quantitative data by converting impedance into cell
index values [16]. In the current study, hESC-and
hiPSC-CMs illustrated comparable baseline parameters
before being subjected to different compounds. How-
ever, while the beating rate of the commercially avail-
able hiPSC-CMs was similar to the native human
heart rate, the beating rate of the homemade hESC-
CMs used in this study was much lower. The spon-
taneous rhythm of hiPSC-CMs tended to be more
consistent and less irregular along with cultivation,
compared with hESC-CMs.
While conventional methods such as the manual patch
clamp provide detailed information of the electrical
activity of cardiomyocytes, the complexity of such tech-
nique necessitates the professional training of the elec-
trophysiologist. In addition, the invasive nature of the
patch clamp makes it difficult to perform long-term in-
vestigations on the same cells. In contrast, the current
platform substantially reduced operator skill require-
ments compared with the patch clamp. Using the
current platform, we have demonstrated recapitulation
of well-characterized drug effects in both hESC- and
hiPSC-CMs. We first tested E-4031, a class III antiar-
rhythmic drug. Our data showed good agreement with a
previous study [17], which showed that the inhibition
rate of 1 μmol/L E-4031 on hERG channel was 99.3%.
We further investigated another typical antiarrhythmic
drug, quinidine, which has been reported to cause severe
arrhythmia due to weak inhibition to potassium currents
[11]. Using the RTCA Cardio system, we quantified the
effect of quinidine on the contractility of hiPSC-CMs
and hESC-CMs. Quinidine reduced the CI value of
hiPSC-CMs and hESC-CMs at the same concentration.
Moreover, quinidine significantly affected hiPSC-CMs
and hESC-CMs at the same concentration and the IC50
of quinidine for both cells were similar in terms of
contractility and beating rhythm. We next investigated
isoprenaline, a nonspecific β-agonist, which has been
shown to strengthen myocardial contractility, accelerate
conduction, and increase beating rate [18]. We measured
the effects of isoprenaline on the contractility of hiPSC-
CMs and hESC-CMs. Isoprenaline significantly increased
the contractility of hiPSC-CMs and hESC-CMs at the
same concentration. Moreover, isoprenaline significantly
increased both the contraction rhythm and amplitude of
hiPSC-CMs and hESC-CMs at the same concentration,
with similar EC50 for both cells. Beside cardiovascular
drugs, we next move on to haloperidol, a dopaminergic
receptor inhibitor used as an anti-schizophrenia drug.
Indeed, several studies have reported that cardiotoxicity is
the most serious adverse reaction of haloperidol. An
overdose of haloperidol can cause QT interval prolonga-
tion, trigger TdPs, and cause sudden death in severe cases
[19, 20]. Studies have shown that haloperidol can reduce
myocardial intracellular free magnesium ion levels and in-
hibit potassium channels, which may be the mechanism
of its cardiotoxicity [21–25]. Here, we quantified the ef-
fects of haloperidol on the contractility of hiPSC-CMs and
hESC-CMs. First, the CI values of hiPSC-CMs and hESC-
CMs were reduced by haloperidol at the same concentra-
tion. Furthermore, we also showed that both the beating
rhythm and amplitude of hiPSC-CMs and hESC-CMs
were reduced by haloperidol at the same concentration.
Overall, we have shown that the current platform
enables quantitative prediction of the potential cardio-
toxicity of drugs at different time points by analyzing the
changes of CI, beating rate, and amplitude of myocardial
cells. We believe this method may reduce animal testing
and improve both throughput and translational rele-
vance of early cardiac safety screening by using hPSC-
CMs. At the same time, researchers can accurately and
sensitively detect the cardiotoxicity of cardiovascular
drugs and non-cardiovascular drugs with a shorter
experimental period and less compounds at the earliest
stages of drug development by using this method, which
may result in lower attrition at the expensive late stages
of the drug discovery process. However, a key limitation
is that hPSC-CMs are functionally and structurally
immature in multiple aspects, such as slow conduction
of electrical impulses, underdeveloped sarcomeres, and
poor electrophysiological properties. Therefore, future
effects should be made to promote the maturation of in
vitro hPSC-CMs for highly efficient and reproducible
cardiotoxicity prediction.
Conclusions
In summary, we found that hESC-CMs and hiPSC-CMs
of different sources present similar responses to mul-
tiple drugs. hPSC-CMs can properly predict the cardio-
toxicity of different compounds. Combining with the
xCELLigence Real-Time Cell Analyzer, hPSC-CMs hold
the potential to increase drug development accuracy
and improve upon industry standards.
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